Summary part 1: 46% of psoriasis patients say that the treatment is worse than the disease, according to the chart on page 8. Note that they are NOT talking about Prurisol, they're talking about currently commercially available treatments.
Page 14, patients are discouraged -- 55% think that it's not realistic to hope for a clearing of the condition.
Page 17 PATENT PENDING on Prurisol manufacturing process. Did we know that already?
Page 24 (we knew this but newer people here might not)
and details on the next clinical trial:
Page 14, patients are discouraged -- 55% think that it's not realistic to hope for a clearing of the condition.
Page 17 PATENT PENDING on Prurisol manufacturing process. Did we know that already?
Page 24 (we knew this but newer people here might not)
Quote:Had one site,
where investigator non-compliance was suspected to have occurred been removed from overall data analyses, 43% of patients in the 200mg
dosing arm would have met the primary endpoint.
and details on the next clinical trial:
Quote:• In the second half of 2016, Cellceutix plans to initiate a Phase 2b trial of Prurisol, testing higher dosing regimens (300mg and 400mg arms),
for the treatment of moderate-to-severe psoriasis. The company also is exploring Prurisol’s use in treating eczema.
3
